These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 7449973)
1. [Determination of chlorphenoxyisobutyrate in the blood of chronic ischemic heart disease patients under prolonged miscleron treatment]. Gneushev ET; Utlinskaia MG; Shitov NN; Senik EA Farmakol Toksikol; 1980; 43(3):335-7. PubMed ID: 7449973 [TBL] [Abstract][Full Text] [Related]
2. Simultaneous GLC determination of clofibrate and clofibric acid in human plasma. Wolf MS; Zimmerman JJ J Pharm Sci; 1980 Jan; 69(1):92-3. PubMed ID: 7354454 [TBL] [Abstract][Full Text] [Related]
3. [Study of pharmacodynamics and pharmacokinetics of clofibrate for the purpose of selection of optimal course of treatment of ischemic heart disease]. Kukes VG; Senik EA; Gneushev ET; Utlinskaia MG; Nasonov AS Ter Arkh; 1979; 51(12):57-61. PubMed ID: 538720 [No Abstract] [Full Text] [Related]
4. Concentration of clofibric acid in blood after the administration of delayed-release form of etofibrate. Vazquez Lopez F; Armijo Castro F; Pire Solis I; Gutierrez Fuentes JA Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):31-5. PubMed ID: 3557726 [TBL] [Abstract][Full Text] [Related]
5. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)]. Ferreira Montero IJ; Gutiérrez Martín M; del Río Ligorit A; Casasnovas Lenguas JA; Cornudella Lacasa R Med Clin (Barc); 1982 May; 78(9):380-5. PubMed ID: 7047926 [No Abstract] [Full Text] [Related]
6. [Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate]. Paltauf F; Pristautz H; el Eisch IA Acta Med Austriaca; 1977; 4(3):120-4. PubMed ID: 930544 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of chronic ischemic cardiopathy with a combination of pyridinolcarbamate and clofibrate]. Guerrera G; Melina D Clin Ter; 1980 Mar; 92(5):533-47. PubMed ID: 7449327 [No Abstract] [Full Text] [Related]
8. The simultaneous analysis of clofibric acid and probenecid and the direct analysis of clofibric acid glucuronide by high-performance liquid chromatography. Veenendaal JR; Meffin PJ J Chromatogr; 1981 Apr; 223(1):147-54. PubMed ID: 7251756 [TBL] [Abstract][Full Text] [Related]
9. [Effect of fenformin and miscleron on the delayed hypersensitivity reaction in breast cancer patients]. Bershteĭn LM; Buslaeva VP; Kondrat'ev VB; Ostroumova MN; Semiglazov VF Vopr Onkol; 1980; 26(12):28-31. PubMed ID: 7467216 [TBL] [Abstract][Full Text] [Related]
10. Study of homocysteine concentration in coronary heart disease patients and comparison of two determination methods. Doncheva N; Penkov A; Velcheva A; Boev M; Popov B; Niagolov Y Ann Nutr Metab; 2007; 51(1):82-7. PubMed ID: 17356259 [TBL] [Abstract][Full Text] [Related]
11. Increased plasma levels of fibrinogen in acute and chronic ischemic coronary syndromes. Abrignani MG; Novo G; Di Girolamo A; Caruso R; Tantillo R; Braschi A; Braschi GB; Strano A; Novo S Cardiologia; 1999 Dec; 44(12):1047-52. PubMed ID: 10687254 [TBL] [Abstract][Full Text] [Related]
12. Bioavailability of plafibride in healthy volunteers. Santaniello E; Conti F; Vilageliu J; Bruseghini L Arzneimittelforschung; 1981; 31(10a):1850-2. PubMed ID: 7198464 [TBL] [Abstract][Full Text] [Related]
13. [Effect of miscleron on various indicators of blood coagulation in ischemic heart disease]. Deriagina GP Kardiologiia; 1977 Mar; 17(3):141-2. PubMed ID: 886690 [No Abstract] [Full Text] [Related]
14. High-performance liquid chromatographic assay for the simultaneous determination of ethyl clofibrate and clofibric acid in plasma. Evaluation of plasma stability of ethyl clofibrate polylactic nanocapsules in human and rat plasmas. Barra J; Taburet AM; Jardel A; Fessi H; Puisieux F J Chromatogr B Biomed Appl; 1994 Nov; 661(1):178-82. PubMed ID: 7866548 [TBL] [Abstract][Full Text] [Related]
15. [Miscleron in the treatment of patients with atherosclerosis of the coronary and cerebal vessels]. Sivkov II; Kukes VG; Kirichenko LL; Fedosova NS; Ishmaeva KA Sov Med; 1971 Sep; 34(9):54-7. PubMed ID: 5121295 [No Abstract] [Full Text] [Related]
16. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476 [TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
18. Effects of pravastatin on the function of dendritic cells in patients with coronary heart disease. Li X; Liu C; Cui J; Dong M; Peng CH; Li QS; Cheng JL; Jiang SL; Tian Y Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):101-6. PubMed ID: 19143751 [TBL] [Abstract][Full Text] [Related]
19. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP; Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014 [TBL] [Abstract][Full Text] [Related]
20. [Rheological properties of the blood in chronic ischemic heart disease]. Romanenko AI Vrach Delo; 1981 Mar; (3):76-81. PubMed ID: 7293149 [No Abstract] [Full Text] [Related] [Next] [New Search]